BINEX Co. Ltd (053030) - Total Assets

Latest as of September 2025: ₩304.35 Billion KRW ≈ $206.25 Million USD

Based on the latest financial reports, BINEX Co. Ltd (053030) holds total assets worth ₩304.35 Billion KRW (≈ $206.25 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BINEX Co. Ltd (053030) shareholders funds for net asset value and shareholders' equity analysis.

BINEX Co. Ltd - Total Assets Trend (2004–2024)

This chart illustrates how BINEX Co. Ltd's total assets have evolved over time, based on quarterly financial data.

BINEX Co. Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

BINEX Co. Ltd's total assets of ₩304.35 Billion consist of 33.1% current assets and 66.9% non-current assets.

Asset Category Amount (KRW) % of Total Assets
Cash & Equivalents ₩-282.74 Million 9.2%
Accounts Receivable ₩16.42 Billion 5.9%
Inventory ₩30.98 Billion 11.1%
Property, Plant & Equipment ₩132.53 Billion 47.4%
Intangible Assets ₩21.15 Billion 7.6%
Goodwill ₩0.00 0.0%

Asset Composition Trend (2004–2024)

This chart illustrates how BINEX Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BINEX Co. Ltd (053030) market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: BINEX Co. Ltd's current assets represent 33.1% of total assets in 2024, an increase from 0.0% in 2004.
  • Cash Position: Cash and equivalents constituted 9.2% of total assets in 2024, up from 7.5% in 2004.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 6.0% in 2004.
  • Asset Diversification: The largest asset category is property, plant & equipment at 47.4% of total assets.

BINEX Co. Ltd Competitors by Total Assets

Key competitors of BINEX Co. Ltd based on total assets are shown below.

Company Country Total Assets
Komipharm International Co. Ltd
KQ:041960
Korea ₩133.65 Billion
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
Korea ₩529.96 Billion
ST Pharm Co.Ltd
KQ:237690
Korea ₩782.57 Billion
Oscotec Inc
KQ:039200
Korea ₩154.14 Billion
Caregen Co.Ltd
KQ:214370
Korea ₩233.98 Billion
NatureCell Co.Ltd
KQ:007390
Korea ₩71.32 Billion
Mezzion Pharma Co.Ltd
KQ:140410
Korea ₩87.88 Billion
Huons Global Co. Ltd
KQ:084110
Korea ₩1.47 Trillion

BINEX Co. Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.62 0.84 4.40
Quick Ratio 0.99 0.52 3.74
Cash Ratio 0.00 0.00 0.00
Working Capital ₩40.93 Billion ₩-15.24 Billion ₩91.74 Billion

BINEX Co. Ltd - Advanced Valuation Insights

This section examines the relationship between BINEX Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.21
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 8.7%
Total Assets ₩279.39 Billion
Market Capitalization $232.91 Million USD

Valuation Analysis

Below Book Valuation: The market values BINEX Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: BINEX Co. Ltd's assets grew by 8.7% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for BINEX Co. Ltd (2004–2024)

The table below shows the annual total assets of BINEX Co. Ltd from 2004 to 2024.

Year Total Assets Change
2024-12-31 ₩279.39 Billion
≈ $189.34 Million
+8.71%
2023-12-31 ₩257.01 Billion
≈ $174.17 Million
-13.87%
2022-12-31 ₩298.41 Billion
≈ $202.23 Million
+9.51%
2021-12-31 ₩272.49 Billion
≈ $184.66 Million
+0.89%
2020-12-31 ₩270.09 Billion
≈ $183.04 Million
+33.19%
2019-12-31 ₩202.78 Billion
≈ $137.42 Million
+6.49%
2018-12-31 ₩190.42 Billion
≈ $129.05 Million
+13.50%
2017-12-31 ₩167.77 Billion
≈ $113.70 Million
-5.27%
2016-12-31 ₩177.10 Billion
≈ $120.02 Million
+0.56%
2015-12-31 ₩176.11 Billion
≈ $119.35 Million
+44.04%
2013-12-31 ₩122.27 Billion
≈ $82.86 Million
-14.97%
2012-12-31 ₩143.80 Billion
≈ $97.45 Million
+42.83%
2011-12-31 ₩100.68 Billion
≈ $68.23 Million
+104.93%
2007-12-31 ₩49.13 Billion
≈ $33.29 Million
+6.10%
2006-12-31 ₩46.30 Billion
≈ $31.38 Million
+8.83%
2005-12-31 ₩42.55 Billion
≈ $28.83 Million
+33.97%
2004-12-31 ₩31.76 Billion
≈ $21.52 Million
--

About BINEX Co. Ltd

KQ:053030 Korea Pharmaceuticals
Market Cap
$232.91 Million
₩343.69 Billion KRW
Market Cap Rank
#15958 Global
#643 in Korea
Share Price
₩11020.00
Change (1 day)
-3.50%
52-Week Range
₩10700.00 - ₩18930.00
All Time High
₩36100.00
About

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; … Read more